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SUPPLEMENTARY NOTES
ABSTRACT
There is strong evidence for the induction of the pro-inflammatory enzymes 5-lipoxygenase (5-LOX) and cyclooxygenase-2 (COX-2) in many types of cancer, including breast cancer. Upregula-tion of both enzymes is associated with promoting tumorigenesis and a negative prognosis of the disease. The 5-LOX (leukotriene) and COX-2 (prostaglandin) pathways have traditionally been viewed as independent biosynthetic routes to eicosanoid lipid hormones, yet recent enzy-mological analyses establish that the 5-LOX product, 5-HETE, is an excellent COX-2 substrate, forming a novel double endoperoxide product that has the potential to evolve into a novel family of biomediators.
In this funding period we have used LC-MS to detect two cellular metabolites that were derived from the novel di-endoperoxide product. The metabolites are similar in molecular weight to the parent di-endoperoxide, and their formation is blocked by presence of the COX-2 inhibitor indomethacin. Detection of these products is a major step forward in establishing a potential novel eicosanoid-forming pathway resulting from the cross-over of the leukotriene and prostaglandin pathways in breast cancer. 
SUBJECT TERMS
Introduction
There is strong evidence for the induction of the pro-inflammatory enzymes 5-lipoxygenase (5-LOX) and cyclooxygenase-2 (COX-2) in many types of cancer, including breast cancer. Upregulation of either enzyme is associated with promoting tumorigenesis and a negative prognosis of the disease. The 5-LOX (leukotriene) and COX-2 (prostaglandin) pathways have traditionally been viewed as independent biosynthetic routes to eicosanoid lipid hormones because either enzyme catalyzes the initiating transformation of arachidonic acid toward their respective pathway. Yet our recent enzymological analyses established that the 5-LOX product, 5-HETE, is an excellent substrate for COX-2, forming a novel di-endoperoxide product [1] ; this di-endoperoxide product has the potential to evolve into a novel family of highly oxygenated eicosanoid biomediators. In this project we tested the hypothesis that novel eicosanoids derived from the cross-over of the 5-LOX and COX-2 pathways can be detected in breast cancer cells that are positive for both enzymes. The long-term goal of this project is to investigate how these novel eicosanoids regulate proliferation and differentiation of breast cancer cells, and thus, to elucidate whether pharmacological manipulation of formation of these novel eicosanoids can provide a strategy for the treatment breast cancer.
Body
Task 1.
To investigate the expression of 5-LOX and COX-2 in breast cancer cell lines
When we initiated work on this task we found that the commercially available antibodies for 5-LOX gave inconsistent and partially false positive signals (Fig. 1) . We decided to generate our own peptide-derived polyclonal antibody for 5-LOX through a commercial outside contractor. The new antibody is quite sensitive and highly specific with no cross-reaction to the other five LOX isoforms. We have now acquired a range of different human breast cancer cell lines and are beginning the screen for expression of 5-LOX and COX-2 using Western blotting. So far, we have not succeeded in detecting expression of either 5-LOX or COX-2 in the breast cancer (MCF-7, MDA-MB-231) or other cancer cell lines (H2122, HCA7) that we have tested.
Task 2.
To investigate the formation of novel 5-LOX/COX-2 dependent metabolites in breast cancer cell lines
We investigated the transformation of 5-HETE in our current model of RAW264.7 macrophages that express high levels of COX-2 upon activation with LPS/IFN-γ. We prepared 5-HETE substrate labeled with deuterium at carbons 5,6,8,9,11,12,14,15 starting from d 8 -arachidonic acid and incubation with recombinant 5-lipoxygenase expressed in Sf9 insect cells.
Using d 8 -labeled 5-HETE 1 we observed formation of the previously identified di-endoperoxide 2 and two novel eicosanoids 3 and 4 when using recombinant human COX-2 (Fig. 2, top panel) . Incubation of 5-HETE with activated RAW264.7 cells gave the same three products, albeit the ratio of products 3 to 4 was changed such that 4 was the more prominent product in the cellular incubations (Fig. 2, middle panel) . The isotopic pattern clearly indicated that these products were derived from 5-HETE, but whereas the di-endoperoxide 2 retained all 8 deuterium labels, the novel metabolites 3 and 4 retained only 6 deuterium atoms and, therefore, have lost 2 labels during the transformation. LC-MS analyses showed that the molecular weight of 3 and 4 is the same as the parent di-endoperoxide 2 (MW = 400; Fig. 2) , and UV analyses indicate the presence of a substituted keto-ene moiety. The di-endoperoxide 2 as well as the novel metabolites 3 and 4 were absent in cells treated with the non-selective COX inhibitor indomethacin, and they were also absent in unstimulated cells (Fig. 2, bottom panel) . The results clearly indicate that the novel eicosanoids 3 and 4 are derived from conversion of 5-HETE 1 by COX-2, and that they are cellular transformation products of the di-endoperoxide 2 that we have previously characterized in vitro [1] . We are now in the process of isolating and structurally identifying eicosanoids 3 and 4.
Task 3.
To treat breast cancer cell lines with the novel metabolite and characterize its effect on differentiation, proliferation, and angiogenesis This task will be addressed during the 12-month no cost extension period from August 1, 2008 -July 31, 2009.
Key Research Accomplishments
• A new antibody for detection of human 5-LOX was designed and generated.
• Two novel eicosanoids derived from the consecutive activities of 5-LOX and COX-2 were detected.
Reportable Outcomes
An abstract reporting the results of task 2 was presented at the AACR Special Conference on Chemical and Biological Aspects of Inflammation and Cancer (October 14-17, 2008) organized by the American Association for Cancer Research:
Markus Griesser, Takashi Suzuki, and Claus Schneider: "Characterization of novel 5-lipoxygenase/cyclooxygenase-2-derived eicosanoids". A copy of the abstract is attached as an appendix.
Conclusion
Our hypothesis of the cross-over of the 5-lipoxygenase and COX-2 pathways in breast cancer was supported by the detection of novel eicosanoids derived from the consecutive enzymatic conversion of arachidonic acid by both enzymes. Characterization of the biological activity of these novel mediators will answer the question whether pharmacological manipulation of this pathway can provide a strategy for the treatment of breast cancer.
